Search

Search Constraints

You searched for: Author/Creator Mach, Nicolas

Search Results

1. Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08. (28th March 2016)

2. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. Issue 26 (10th September 2021)

3. Comparison of the incidence of osteoradionecrosis with conventional radiotherapy and intensity‐modulated radiotherapy. Issue 11 (31st May 2016)

4. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. (October 2022)

5. P-190 Personalized Immunotherapy with Cell-Encapsulation Technology for 2nd line R/M HNSCC: Safety and Early Efficacy Data from all HNSCC patients treated with MVX-ONCO-1 in two clinical trials. (July 2021)

8. Giant Cell Tumor of Bone With Pseudosarcomatous Changes Leading to Premature Denosumab Therapy Interruption: A Case Report With Review of the Literature. (June 2016)

9. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Issue 10167 (12th January 2019)

10. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. (14th May 2020)